472 related articles for article (PubMed ID: 30400108)
1. The severity and associated comorbidities of retinopathy of prematurity among micro-premature infants with birth weights less than 750 grams.
Beck K; Young R; Read S; Harper H; Desireddi J; Harper CA
J Neonatal Perinatal Med; 2019; 12(1):41-45. PubMed ID: 30400108
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey.
Gunay M; Sukgen EA; Celik G; Kocluk Y
Curr Eye Res; 2017 Mar; 42(3):462-469. PubMed ID: 27420302
[TBL] [Abstract][Full Text] [Related]
3. Ranibizumab injection and laser photocoagulation to treat type 1 retinopathy of prematurity after 40 weeks post menstrual age: a retrospective case series study.
Lyu J; Zhang Q; Chen C; Xu Y; Ji X; Zhao P
BMC Ophthalmol; 2019 Feb; 19(1):60. PubMed ID: 30808338
[TBL] [Abstract][Full Text] [Related]
4. Combined intravitreal ranibizumab and zone I sparing laser ablation in infants with posterior zone I retinopathy of prematurity.
Parchand SM; Agrawal D; Gangwe A; Saraogi T; Agrawal D
Indian J Ophthalmol; 2021 Aug; 69(8):2164-2170. PubMed ID: 34304202
[TBL] [Abstract][Full Text] [Related]
5. RATES AND RISK FACTORS FOR RECURRENCE OF RETINOPATHY OF PREMATURITY AFTER LASER OR INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR MONOTHERAPY.
Ling KP; Liao PJ; Wang NK; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC; Wu WC
Retina; 2020 Sep; 40(9):1793-1803. PubMed ID: 31800460
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Intravitreal Bevacizumab, Intravitreal Ranibizumab and Laser Photocoagulation for Treatment of Type 1 Retinopathy of Prematurity in Turkish Preterm Children.
Kabataş EU; Kurtul BE; Altıaylık Özer P; Kabataş N
Curr Eye Res; 2017 Jul; 42(7):1054-1058. PubMed ID: 28128986
[TBL] [Abstract][Full Text] [Related]
7. Screening premature infants for retinopathy of prematurity in a tertiary hospital in Saudi Arabia.
Mgharbil E; Raffa LH; Alessa S; Alamri A
Ann Saudi Med; 2020; 40(2):87-93. PubMed ID: 32241163
[TBL] [Abstract][Full Text] [Related]
8. Low-dose ranibizumab as primary treatment of posterior type I retinopathy of prematurity.
Ells AL; Wesolosky JD; Ingram AD; Mitchell PC; Platt AS
Can J Ophthalmol; 2017 Oct; 52(5):468-474. PubMed ID: 28985806
[TBL] [Abstract][Full Text] [Related]
9. Treatment for stage 4A retinopathy of prematurity: laser and/or ranibizumab.
Sukgen EA; Koçluk Y
Graefes Arch Clin Exp Ophthalmol; 2017 Feb; 255(2):263-269. PubMed ID: 27495302
[TBL] [Abstract][Full Text] [Related]
10. Primary intravitreal ranibizumab for high-risk retinopathy of prematurity.
Baumal CR; Goldberg RA; Fein JG
Ophthalmic Surg Lasers Imaging Retina; 2015 Apr; 46(4):432-8. PubMed ID: 25970863
[TBL] [Abstract][Full Text] [Related]
11. SHORT-TERM OUTCOMES AFTER INTRAVITREAL INJECTIONS OF CONBERCEPT VERSUS RANIBIZUMAB FOR THE TREATMENT OF RETINOPATHY OF PREMATURITY.
Jin E; Yin H; Li X; Zhao M
Retina; 2018 Aug; 38(8):1595-1604. PubMed ID: 28699927
[TBL] [Abstract][Full Text] [Related]
12. COMPARISON OF INTRAVITREAL INJECTION OF RANIBIZUMAB VERSUS LASER THERAPY FOR ZONE II TREATMENT-REQUIRING RETINOPATHY OF PREMATURITY.
Zhang G; Yang M; Zeng J; Vakros G; Su K; Chen M; Li H; Tian R; Li N; Tang S; He H; Tan W; Song X; Zhuang R;
Retina; 2017 Apr; 37(4):710-717. PubMed ID: 27529839
[TBL] [Abstract][Full Text] [Related]
13. Aqueous cytokine levels associated with severity of type 1 retinopathy of prematurity and treatment response to ranibizumab.
Lyu J; Zhang Q; Jin H; Xu Y; Chen C; Ji X; Zhang X; Rao Y; Zhao P
Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1469-1477. PubMed ID: 29948178
[TBL] [Abstract][Full Text] [Related]
14. Outcomes and prognostic factors for aggressive posterior retinopathy of prematurity following initial treatment with intravitreal ranibizumab.
Tong Q; Yin H; Zhao M; Li X; Yu W
BMC Ophthalmol; 2018 Jun; 18(1):150. PubMed ID: 29940900
[TBL] [Abstract][Full Text] [Related]
15. [Laser treatment or intravitreal VEGF inhibition for aggressive posterior retinopathy of prematurity?].
Barth T; Hufendiek K; Helbig H; Oberacher-Velten I
Ophthalmologe; 2015 Jun; 112(6):520-4. PubMed ID: 25573085
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of early versus deferred laser after intravitreal ranibizumab in aggressive posterior retinopathy of prematurity.
Gangwe AB; Agrawal D; Gangrade AK; Parchand SM; Agrawal D; Azad RV
Indian J Ophthalmol; 2021 Aug; 69(8):2171-2176. PubMed ID: 34304203
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease.
Menke MN; Framme C; Nelle M; Berger MR; Sturm V; Wolf S
BMC Ophthalmol; 2015 Mar; 15():20. PubMed ID: 25886603
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of Severe Retinopathy of Prematurity in Infants with Birth Weight above 1500 Grams at a Referral Center in Turkey.
Gunay M; Celik G; Tuten A; Karatekin G; Bardak H; Ovali F
PLoS One; 2016; 11(8):e0161692. PubMed ID: 27548628
[TBL] [Abstract][Full Text] [Related]
19. FLUORESCEIN ANGIOGRAPHIC EVALUATION OF PERIPHERAL RETINAL VASCULATURE AFTER PRIMARY INTRAVITREAL RANIBIZUMAB FOR RETINOPATHY OF PREMATURITY.
Harper CA; Wright LM; Young RC; Read SP; Chang EY
Retina; 2019 Apr; 39(4):700-705. PubMed ID: 29300248
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity.
Karkhaneh R; Khodabande A; Riazi-Eafahani M; Roohipoor R; Ghassemi F; Imani M; Dastjani Farahani A; Ebrahimi Adib N; Torabi H
Acta Ophthalmol; 2016 Sep; 94(6):e417-20. PubMed ID: 27009449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
